Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine.

Autor:	Schrecker J; a Healthcare Services , Aegis Sciences Corporation , Nashville , TN , USA., Puet B; a Healthcare Services , Aegis Sciences Corporation , Nashville , TN , USA., Hild C; b Quality , Aegis Sciences Corporation , Nashville , TN , USA., Schwope DM; c Research and Development , Aegis Sciences Corporation , Nashville , TN , USA.
Jazyk:	angličtina
Zdroj:	Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2018 Sep; Vol. 14 (9), pp. 973-978. Date of Electronic Publication: 2018 Aug 31.
DOI:	10.1080/17425255.2018.1509953
Abstrakt:	Background: Identification of drug-drug interactions (DDIs) typically relies on patient medication lists which are prone to inaccuracies. This study describes use of a mass spectrometry test to detect recently ingested substances in urine with subsequent identification of DDIs. Research Design and Methods: This was a retrospective analysis of the prevalence of DDIs identified in patients with chronic pain, addiction and/or behavioral health conditions in the U.S. Relationships between patient demographics, polypharmacy and the occurrence of DDIs were also described. Results: Of 15,004 patients, 2964 (20%) had a DDI identified. There was a positive association between the number of substances detected in urine and the number of interactions identified (r = 0.5033, p-value = 0.0001). Of patients with polypharmacy, 15.6% had contraindicated or severe interactions identified compared to only 3.2% of those without polypharmacy. For polypharmacy patients, the youngest population studied had a much higher likelihood of having one or more DDIs identified compared to the other age groups (p-value = 0.0002). Conclusions: By utilizing a mass spectrometry test to objectively detect recently ingested substances followed by identification of DDIs, healthcare providers may be able to better characterize the true incidence of DDIs. Study findings may not be generalizable to healthcare populations outside of pain management, addiction treatment, and behavioral health.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu